Cancers, Free Full-Text
Por um escritor misterioso
Descrição
Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Oxidative stress, inflammation, and cancer: How are they linked? - ScienceDirect
Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization
Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset
Pancreatic Cancer Action Network – Research, Patient Support, Resources
Cancer-Free, Third Edition by Bill Henderson - Audiobook
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Hallmarks of Cancer: The Next Generation: Cell
What is secondary lung cancer?
An Introduction to Human Cancers
Join a FREE Breast Cancer Survivorship Program
Hallmarks of Cancer: The Next Generation: Cell
de
por adulto (o preço varia de acordo com o tamanho do grupo)
